Zilver PTX - The drug-eluting SFA stent.

Reduce your SFA restenosis rate by 50% with this combination therapy device.

Zilver® PTX® combines the benefits of mechanical and drug therapies, creating an effective treatment no single-therapy device can match. This combination therapy has been proven in complementary randomized and single-arm clinical trials. In the randomized trial, Zilver PTX achieved a 50% reduction in restenosis at two years compared with bare-metal stenting.1

Mechanical Therapy (Counteracts acute recoil to maintain patency) + Drug Therapy (Prevents cell proliferation for the life of the coil).

1 Dake M. The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Presented at: 7th edition of the Leipzig Interventional Course (LINC) 2011; January 19-22, 2011; Leipzig, Germany.

Instructions for Use:

Please refer to the Zilver PTX IFU for indications, contraindications, warnings, precautions and potential adverse events. PDF Download »

Explore the data from the Zilver PTX clinical trials.
Available in 6 Fr and lengths up to 120 mm.

Available in 6 Fr and lengths up to 120 mm.